%0 Journal Article %1 pillai_outer_2005 %A Pillai, Subramonia %A Howell, Alan %A Alexander, Kristin %A Bentley, B Erin %A Jiang, Han-Qian %A Ambrose, Karita %A Zhu, Duzhang %A Zlotnick, Gary %D 2005 %J Vaccine %K Animals, Antibodies, B, Bacterial Bacterial, Humans, Infections, Membrane Meningococcal Mice, Neisseria Outer Proteins, Rats, Serogroup Synthetic Vaccines, meningitidis, {Sprague-Dawley,} %N 17-18 %P 2206--9 %R S0264-410X(05)00061-7 %T Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B %V 23 %X A family of outer membrane lipoproteins of Neisseria meningitidis, LP2086, has been shown to induce serum bactericidal activity against a broad variety of meningococcal strains. Two sub-families of serologically distinct LP2086 proteins (A and B) have been identified. In the present study, we have shown that polyclonal anti-serum against rLP2086 is protective in vivo in an infant rat passive-protection model. Additionally, the LP2086 protein is displayed on the surface of 91\% meningococcal strains as measured in a whole cell ELISA using polyclonal anti-sera raised against these proteins. We also demonstrate based on the reactivity of anti-rLP2086 antibody with recombinantly expressed C- and N-terminal fragments of rLP2086 in a Western blot assay that the C-terminal fragment of LP2086 dictates sub-family specificity and the N-terminal fragment determines the family specificity. A formulation containing family A and B of LP2086 potentially would provide broad protection against a majority of Neisseria meningitidis strains.

@article{pillai_outer_2005, abstract = {A family of outer membrane lipoproteins of Neisseria meningitidis, {LP2086,} has been shown to induce serum bactericidal activity against a broad variety of meningococcal strains. Two sub-families of serologically distinct {LP2086} proteins {(A} and B) have been identified. In the present study, we have shown that polyclonal anti-serum against {rLP2086} is protective in vivo in an infant rat passive-protection model. Additionally, the {LP2086} protein is displayed on the surface of 91\% meningococcal strains as measured in a whole cell {ELISA} using polyclonal anti-sera raised against these proteins. We also demonstrate based on the reactivity of {anti-rLP2086} antibody with recombinantly expressed C- and N-terminal fragments of {rLP2086} in a Western blot assay that the C-terminal fragment of {LP2086} dictates sub-family specificity and the N-terminal fragment determines the family specificity. A formulation containing family A and B of {LP2086} potentially would provide broad protection against a majority of Neisseria meningitidis strains.}, added-at = {2011-03-11T10:05:34.000+0100}, author = {Pillai, Subramonia and Howell, Alan and Alexander, Kristin and Bentley, B Erin and Jiang, {Han-Qian} and Ambrose, Karita and Zhu, Duzhang and Zlotnick, Gary}, biburl = {https://www.bibsonomy.org/bibtex/2fc2eef7b1337398cd489bda37881ce0c/jelias}, doi = {S0264-410X(05)00061-7}, interhash = {a611de6d33a03b0365f0197c43a9ba6e}, intrahash = {fc2eef7b1337398cd489bda37881ce0c}, issn = {{0264-410X}}, journal = {Vaccine}, keywords = {Animals, Antibodies, B, Bacterial Bacterial, Humans, Infections, Membrane Meningococcal Mice, Neisseria Outer Proteins, Rats, Serogroup Synthetic Vaccines, meningitidis, {Sprague-Dawley,}}, month = mar, note = {{PMID:} 15755596}, number = {17-18}, pages = {2206--9}, timestamp = {2011-03-11T10:06:33.000+0100}, title = {Outer membrane protein {(OMP)} based vaccine for Neisseria meningitidis serogroup B}, volume = 23, year = 2005 }